Clinical Commander

Back to dossier
geriatrics.dementia-lewy-body.core.v1PRODUCTION
geriatrics.dementia-lewy-body.core.v1

Dementia with Lewy bodies

general_internal_medicinechronicgeriatricadult
Hard-required inputs
0 / 14
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Confirm scope: chronic insidious progressive cognitive decline in an older adult with Lewy-spectrum features; not acute delirium and not rapidly progressive (<1-2y → CJD) dementia (McKeith 2017)

Inputs
2
Actions
0
Advance rule
Set
Advance when

Chronic progressive cognitive complaint with ≥1 Lewy-spectrum pointer established; acute/rapid course excluded or pivoted (McKeith 2017)

Patient inputs (15)

Fluctuating cognition, recurrent visual hallucinations, RBD, spontaneous parkinsonism — number of core features drives probable vs possible DLB (McKeith 2017)

Informant required — fluctuations, hallucinations, dream-enactment, and falls are often unreported by the patient (McKeith 2017)

RBD (dream-enactment, REM-without-atonia on PSG) is a core feature and may precede cognition by years; high specificity for Lewy pathology (McKeith 2017)

Orthostatic hypotension, constipation, urinary dysfunction, syncope — supportive features and key safety/management targets (McKeith 2017)

Anticholinergics/dopamine agonists/amantadine/benzodiazepines worsen cognition, hallucinations, falls — deprescribing target; antipsychotic exposure is a red flag (AGS Beers 2023)

Repeated falls/syncope (parkinsonism + orthostatic hypotension) — supportive feature driving a falls/autonomic program (McKeith 2017)

Caregiver availability/burden + decision-making capacity drive neuroleptic-avoidance education, ACP, driving, and disposition (NICE NG97)

The 1-year rule: cognitive onset before/within 1y of parkinsonism = DLB; dementia >1y after established PD = PDD (McKeith 2017)

Insidious progressive course over months-to-years distinguishes DLB from delirium and rapidly progressive dementia; defines the 1-year rule vs PD (McKeith 2017)

DLB onset typically >60y; early onset prompts atypical/genetic and prion considerations (McKeith 2017)

B12 deficiency is a reversible/contributing cause — mandatory exclusion before attributing to DLB (NICE NG97)

Hypothyroidism is a reversible/contributing cause — mandatory exclusion (NICE NG97)

MRI (or CT) excludes NPH/subdural/tumor/strategic infarct; relative medial-temporal preservation supports DLB over AD (McKeith 2017)

SEVERE neuroleptic hypersensitivity — prior antipsychotic exposure/reaction is a major safety datum; future antipsychotics may be fatal (McKeith 2017)

Reduced DAT-SPECT/PET striatal uptake, abnormal MIBG cardiac scintigraphy, PSG-confirmed REM-without-atonia are indicative biomarkers raising diagnostic certainty (McKeith 2017)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (6)

6 need judgement
  • informationallife_threateningneuroleptic_induced_severe_sensitivity_reaction
    Severe neuroleptic sensitivity reaction in DLB after an antipsychotic — acute parkinsonism, NMS-like (rigidity/fever/autonomic instability/elevated CK), autonomic collapse, or rapid decline (McKeith 2017)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningantipsychotic_exposure_in_suspected_dlb
    Any antipsychotic given or being considered in a patient with visual hallucinations, fluctuation, RBD, or parkinsonism (suspected/confirmed DLB) (McKeith 2017)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningdelirium_superimposed_on_dlb
    Acute fluctuating inattention/altered consciousness superimposed on baseline DLB fluctuation (commonly missed) (NICE NG97)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveresevere_orthostatic_syncope_or_recurrent_injurious_falls
    Severe symptomatic orthostatic hypotension with syncope, or recurrent injurious falls from parkinsonism + autonomic failure (McKeith 2017)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveredisabling_refractory_psychosis
    Severe distressing or dangerous psychosis/agitation refractory to trigger treatment + non-pharm in DLB (McKeith 2017)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatereversible_cause_identified
    Significant B12 deficiency, hypothyroidism, NPH triad, or anticholinergic/sedative-driven decline identified (NICE NG97)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

INITIAL_WORKUPrequiredDrives screening
Loading…

Recommended regimen

DLB care ladder — confirm + neuroleptic-avoidance alert → ChEI first-line → cautious levodopa → RBD melatonin → autonomic OH → psychosis (AVOID antipsychotics) → deprescribe + caregiver/ACP/falls
axis: dlb_care_ladderstep 1 - Step 1 — Confirm DLB (McKeith 2017) + raise the NEUROLEPTIC-AVOIDANCE ALERT (FIRST, before any psychotropic)
Selected step "Step 1 — Confirm DLB (McKeith 2017) + raise the NEUROLEPTIC-AVOIDANCE ALERT (FIRST, before any psychotropic)" — Any patient with probable/possible DLB or Lewy-spectrum features before starting DLB-directed therapy
  • mckeith_2017_diagnostic_confirmation
    first line
    diagnostic_action
    triggers: dementia_plus_core_or_indicative_biomarker
    McKeith 2017 — dementia + ≥2 core (fluctuation, visual hallucinations, RBD, spontaneous parkinsonism) OR 1 core + ≥1 indicative biomarker (DAT-SPECT/MIBG/PSG) = probable DLB; apply the 1-year rule vs PDD
  • neuroleptic_avoidance_alert_card_and_ehr_flag
    first line
    safety_action
    triggers: dlb_confirmed_or_suspected
    McKeith 2017 / LBDA — SEVERE neuroleptic hypersensitivity (irreversible parkinsonism, NMS-like, autonomic collapse, rapid decline, death) in up to ~50%; patient-held alert card + EHR allergy/alert flag + caregiver and clinician education BEFORE any psychotropic
  • reversible_cause_workup
    first line
    diagnostic_action
    triggers: cognitive_decline_new
    NICE NG97 — B12, TSH, depression (GDS-15), medication/anticholinergic burden, structural MRI (NPH/subdural/tumor) excluded/treated before DLB attribution
  • dlb_indicative_biomarker_imaging
    add on
    diagnostic_action
    triggers: diagnosis_uncertain
    McKeith 2017 — DAT-SPECT/PET, I-123 MIBG cardiac scintigraphy, or PSG-confirmed REM-without-atonia raise diagnostic certainty (possible → probable DLB)

outpatient playbook — drug actions (6)

  1. 1. McKeith 2017 confirmation + neuroleptic-avoidance alert card/EHR flag + reversible-cause workup
    n/a • n/a • at diagnosis
    trigger: DLB suspected/confirmed
    McKeith 2017 / LBDA — alert FIRST; severe neuroleptic hypersensitivity is potentially fatal
  2. 2. rivastigmine (or donepezil) ± memantine
    rivastigmine 1.5 mg BID up-titrate (or patch); memantine add-on moderate-severe • PO/transdermal • BID / once daily
    trigger: Cognitive impairment and/or visual hallucinations
    McKeith 2017 — ChEI first-line for cognition AND hallucinations in DLB
  3. 3. carbidopa-levodopa (lowest effective dose)
    25/100 half-to-one tab daily, titrate slowly • PO • daily→TID
    trigger: Disabling parkinsonism
    McKeith 2017 — lowest dose; AVOID DA agonists/anticholinergics/amantadine
  4. 4. melatonin (clonazepam only if refractory)
    melatonin 3 mg qHS titrate to 6-12 mg • PO • nightly
    trigger: Injurious RBD/dream-enactment
    McKeith 2017 — melatonin first-line; limit clonazepam (sedation/falls)
  5. 5. midodrine / fludrocortisone / droxidopa
    after non-pharm: midodrine 2.5 mg TID daytime titrate • PO • TID daytime
    trigger: Symptomatic orthostatic hypotension
    McKeith 2017 — non-pharm first; monitor supine hypertension
  6. 6. quetiapine or pimavanserin (last resort only)
    quetiapine 12.5 mg qHS lowest effective, time-limited • PO • lowest effective, review early
    trigger: Severe distressing psychosis, triggers + non-pharm failed, truly unavoidable
    McKeith 2017 — AVOID antipsychotics; if unavoidable, cautious low-dose quetiapine/pimavanserin only

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Recurrent well-formed visual hallucinations with progressive cognitive decline (McKeith 2017 core); Fluctuating attention/alertness + spontaneous parkinsonism (bradykinesia/rigidity/rest tremor) with dementia (McKeith 2017 core); Dream-enactment / REM sleep behavior disorder (may predate cognition by years) — prodromal/core DLB (McKeith 2017).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Dementia with Lewy bodies** (geriatrics.dementia-lewy-body.core.v1).
Phenotype framing: DLB (≥2 core, or 1 core + ≥1 indicative biomarker = probable) vs Alzheimer disease (early prominent amnesia, late hallucinations), vascular dementia (stepwise, infarct burden, early gait/executive), Parkinson disease / PDD (the 1-year rule), delirium (acute fluctuating inattention — but frequently superimposed), and CJD (rapidly progressive) (McKeith 2017)
Scope: Confirm scope: chronic insidious progressive cognitive decline in an older adult with Lewy-spectrum features; not acute delirium and not rapidly progressive (<1-2y → CJD) dementia (McKeith 2017)

No severity triggers fired against current inputs.

Plan

Regimen axis: **DLB care ladder — confirm + neuroleptic-avoidance alert → ChEI first-line → cautious levodopa → RBD melatonin → autonomic OH → psychosis (AVOID antipsychotics) → deprescribe + caregiver/ACP/falls** — step "Step 1 — Confirm DLB (McKeith 2017) + raise the NEUROLEPTIC-AVOIDANCE ALERT (FIRST, before any psychotropic)".
1. mckeith_2017_diagnostic_confirmation (diagnostic_action, first line) — McKeith 2017 — dementia + ≥2 core (fluctuation, visual hallucinations, RBD, spontaneous parkinsonism) OR 1 core + ≥1 indicative biomarker (DAT-SPECT/MIBG/PSG) = probable DLB; apply the 1-year rule vs PDD
2. neuroleptic_avoidance_alert_card_and_ehr_flag (safety_action, first line) — McKeith 2017 / LBDA — SEVERE neuroleptic hypersensitivity (irreversible parkinsonism, NMS-like, autonomic collapse, rapid decline, death) in up to ~50%; patient-held alert card + EHR allergy/alert flag + caregiver and clinician education BEFORE any psychotropic
3. reversible_cause_workup (diagnostic_action, first line) — NICE NG97 — B12, TSH, depression (GDS-15), medication/anticholinergic burden, structural MRI (NPH/subdural/tumor) excluded/treated before DLB attribution
4. dlb_indicative_biomarker_imaging (diagnostic_action, add on) — McKeith 2017 — DAT-SPECT/PET, I-123 MIBG cardiac scintigraphy, or PSG-confirmed REM-without-atonia raise diagnostic certainty (possible → probable DLB)

Setting playbook (outpatient) — Diagnose DLB (McKeith 2017), raise the neuroleptic-avoidance alert, establish ChEI-first symptomatic therapy, manage parkinsonism/RBD/autonomic/psychosis safely, and embed caregiver education + ACP + falls program
5. McKeith 2017 confirmation + neuroleptic-avoidance alert card/EHR flag + reversible-cause workup n/a n/a at diagnosis — DLB suspected/confirmed (McKeith 2017 / LBDA — alert FIRST; severe neuroleptic hypersensitivity is potentially fatal)
6. rivastigmine (or donepezil) ± memantine rivastigmine 1.5 mg BID up-titrate (or patch); memantine add-on moderate-severe PO/transdermal BID / once daily — Cognitive impairment and/or visual hallucinations (McKeith 2017 — ChEI first-line for cognition AND hallucinations in DLB)
7. carbidopa-levodopa (lowest effective dose) 25/100 half-to-one tab daily, titrate slowly PO daily→TID — Disabling parkinsonism (McKeith 2017 — lowest dose; AVOID DA agonists/anticholinergics/amantadine)
8. melatonin (clonazepam only if refractory) melatonin 3 mg qHS titrate to 6-12 mg PO nightly — Injurious RBD/dream-enactment (McKeith 2017 — melatonin first-line; limit clonazepam (sedation/falls))
9. midodrine / fludrocortisone / droxidopa after non-pharm: midodrine 2.5 mg TID daytime titrate PO TID daytime — Symptomatic orthostatic hypotension (McKeith 2017 — non-pharm first; monitor supine hypertension)
10. quetiapine or pimavanserin (last resort only) quetiapine 12.5 mg qHS lowest effective, time-limited PO lowest effective, review early — Severe distressing psychosis, triggers + non-pharm failed, truly unavoidable (McKeith 2017 — AVOID antipsychotics; if unavoidable, cautious low-dose quetiapine/pimavanserin only)

Non-pharmacologic actions:
- Patient-held neuroleptic-avoidance alert card + EHR allergy/alert flag + clinician/caregiver education
- Caregiver education on fluctuations + hallucination management; respite/support referral
- Advance care planning, surrogate, driving assessment, financial/legal capacity early (fluctuating capacity)
- Multifactorial falls/syncope program; orthostatic-BP optimization; deprescribe hypotensive/sedating drugs
- Rigorously deprescribe anticholinergics; avoid benzodiazepines; treat depression with non-anticholinergic agents
- Psychosis/agitation: trigger search (delirium, pain, infection, constipation, environment) + non-pharm before any drug

AVOID / contraindication checks:
- Avoid_all_antipsychotics_in_DLB_severe_neuroleptic_hypersensitivity_potentially_fatal (McKeith 2017)
- If_psychotropic_unavoidable_use_lowest_dose_quetiapine_or_pimavanserin_with_extreme_caution_and_monitoring (McKeith 2017)
- Avoid_dopamine_agonists_anticholinergic_antiparkinsonians_and_amantadine_worsen_hallucinations_orthostasis (McKeith 2017)
- Levodopa_lowest_effective_dose_worsens_hallucinations_and_orthostatic_hypotension (McKeith 2017)
- Limit_or_avoid_clonazepam_for_RBD_sedation_falls_cognitive_worsening_prefer_melatonin (McKeith 2017)
- Avoid_benzodiazepines_in_DLB_falls_confusion_delirium (AGS Beers 2023)
- Rigorously_deprescribe_anticholinergics_worsen_cognition_and_hallucinations (AGS Beers 2023)
- Avoid_anticholinergic_antidepressants_TCA_paroxetine_for_DLB_depression (AGS Beers 2023)
- Cholinesterase_inhibitor_bradycardia_syncope_caution_baseline_HR_and_autonomic_status (McKeith 2017)
- Low_threshold_for_superimposed_delirium_avoid_antipsychotic_treat_precipitant (NICE NG97)

Monitoring

Regimen monitoring:
- cognitive and functional MoCA ADL IADL and fluctuation tracking q6-12mo (McKeith 2017)
- parkinsonism progression and levodopa tolerability hallucinations orthostasis (McKeith 2017)
- orthostatic vitals lying and standing BP at each visit (McKeith 2017)
- RBD control and bedroom safety review (McKeith 2017)
- cholinesterase inhibitor tolerability GI HR syncope at each titration (McKeith 2017)
- ACTIVE neuroleptic exposure surveillance medication reconciliation every encounter (McKeith 2017)
- anticholinergic burden ACB reassessment after deprescribing (AGS Beers 2023)
- caregiver burden screen each visit (NICE NG97)

Setting (outpatient) monitoring:
- MoCA/ADL/IADL + fluctuation tracking q6-12mo (McKeith 2017)
- Lying/standing BP each visit; levodopa hallucination/orthostasis tolerability (McKeith 2017)
- ChEI tolerability — GI, HR/syncope at each titration (McKeith 2017)
- ACTIVE neuroleptic-exposure surveillance — medication reconciliation every encounter (McKeith 2017)
- Caregiver burden screen each visit (NICE NG97)

Follow-up plan: Advance care planning revisited at each transition; neuroleptic-avoidance card/alert reinforced with patient, caregivers, and all treating clinicians; driving/finances/capacity reviewed; falls/autonomic program maintained; caregiver respite/support; palliative/end-of-life planning and ChEI/levodopa deprescribing decisions in advanced disease (NICE NG97)
- Close-out criterion: ACP documented; neuroleptic-avoidance alert disseminated; caregiver support arranged; next cognitive/autonomic review scheduled (NICE NG97)

Monitoring phase: Cognitive/functional re-assessment (MoCA + ADL/IADL) and fluctuation tracking every 6-12 months; parkinsonism progression and levodopa tolerability (hallucinations/orthostasis); orthostatic vitals at each visit; RBD control; ChEI tolerability (GI, bradycardia/syncope); ACTIVE neuroleptic-exposure surveillance (medication reconciliation every encounter); caregiver burden each visit (McKeith 2017; NICE NG97)

Disposition

Current setting: outpatient — Diagnose DLB (McKeith 2017), raise the neuroleptic-avoidance alert, establish ChEI-first symptomatic therapy, manage parkinsonism/RBD/autonomic/psychosis safely, and embed caregiver education + ACP + falls program

Disposition criteria:
- Continue outpatient neurology/cognitive-disorders/geriatrics co-management when stable (NICE NG97)
- Refer long-term care/placement planning as disease advances and caregiver capacity is exceeded (NICE NG97)

Escalation triggers (move to higher acuity):
- Antipsychotic given/considered or severe neuroleptic sensitivity reaction → urgent neurology + STOP agent (McKeith 2017)
- Superimposed delirium or acute deterioration → inpatient workup (AVOID antipsychotic) (NICE NG97)
- Severe orthostatic syncope / recurrent injurious falls → urgent autonomic/falls evaluation (McKeith 2017)
- Disabling refractory psychosis / caregiver breakdown → inpatient/old-age-psychiatry (NICE NG97)
- Rapid progression (<1-2y) → rapid-dementia workup (CJD/autoimmune) (McKeith 2017)

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Severe neuroleptic sensitivity reaction in DLB after an antipsychotic — acute parkinsonism, NMS-like (rigidity/fever/autonomic instability/elevated CK), autonomic collapse, or rapid decline (McKeith 2017)
- [LIFE_THREATENING] Any antipsychotic given or being considered in a patient with visual hallucinations, fluctuation, RBD, or parkinsonism (suspected/confirmed DLB) (McKeith 2017)
- [LIFE_THREATENING] Acute fluctuating inattention/altered consciousness superimposed on baseline DLB fluctuation (commonly missed) (NICE NG97)

Citations

- McKeith 2017 DLB Consortium diagnostic criteria (Neurology) + 2024-2025 DLB management reviews + Lewy Body Dementia Association (LBDA); NICE NG97 Dementia; AGS Beers 2023 [PMID:28592453](https://pubmed.ncbi.nlm.nih.gov/28592453/)
- Cited evidence (PMID 32238510) [PMID:32238510](https://pubmed.ncbi.nlm.nih.gov/32238510/)
- Cited evidence (PMID 15184601) [PMID:15184601](https://pubmed.ncbi.nlm.nih.gov/15184601/)
- Cited evidence (PMID 24987007) [PMID:24987007](https://pubmed.ncbi.nlm.nih.gov/24987007/)
- Cited evidence (PMID 25062946) [PMID:25062946](https://pubmed.ncbi.nlm.nih.gov/25062946/)

Last reconciled with current guidelines: 2026-05-16.
References
  • McKeith 2017 DLB Consortium diagnostic criteria (Neurology) + 2024-2025 DLB management reviews + Lewy Body Dementia Association (LBDA); NICE NG97 Dementia; AGS Beers 2023 — PMID:28592453
  • Cited evidence (PMID 32238510) — PMID:32238510
  • Cited evidence (PMID 15184601) — PMID:15184601
  • Cited evidence (PMID 24987007) — PMID:24987007
  • Cited evidence (PMID 25062946) — PMID:25062946